Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 97–108 of 134 articles · Explore study findings

Clear search and filters

  • Explore study findings

    What FDA found about human exposure to PEG-MGF

    PEG-MGF is a name for a synthetic mechano growth factor-related peptide linked to polyethylene glycol, or PEG. The name is related to research on insulin-like growth factor I, or IGF-I.

    PEG-MGF1 source (2026)

  • Explore study findings

    What a withdrawn compounding nomination means

    PEG-MGF refers to a synthetic MGF-related peptide joined to polyethylene glycol, or PEG. The FDA has tracked it separately from unmodified mechano growth factor. Its 2026 records illustrate the difference between a nomination to a compounding list and evidence supporting an approved drug.

    PEG-MGF3 sources (2026)

  • Explore study findings

    Why chemical modification can change more than persistence

    PEG-MGF is a synthetic MGF-related peptide attached to polyethylene glycol. An older laboratory study examined a different substance, PEG-linked full-length IGF-I. It asked a useful question for interpreting any modified molecule.

    PEG-MGF2 sources (2011, 2026)

  • Explore study findings

    What Pinealon Changed in Neurons Grown From Older Donor Cells

    Pinealon is a synthetic three-amino-acid peptide also known as EDR. Researchers have studied it in models of nerve cells and aging.

    Pinealon1 source (2024)

  • Explore study findings

    What Participants Reported After the Bremelanotide Trials

    Bremelanotide, also called PT-141, was evaluated in the RECONNECT trials for hypoactive sexual desire disorder. An older exit-study report examined what some trial participants said about their experience.

    PT-1412 sources (2021, 2026)

  • Explore study findings

    What TRIUMPH-1 established about average weight change

    Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied.

    RETA GLP-32 sources (2025, 2026)

  • Explore study findings

    Why TRIUMPH-2 enrolled adults with type 2 diabetes

    Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight.

    RETA GLP-32 sources (2026)

  • Explore study findings

    What retatrutide blood samples reveal about changing fuel use

    Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” label refers to the catalog entry.

    RETA GLP-31 source (2026)

  • Explore study findings

    What a retatrutide outcomes trial can establish about kidney events

    Retatrutide is an investigational peptide that acts on GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This catalog entry names the two together.

    RETA / IGF-1 LR33 sources (1995–2026)

  • Explore study findings

    What a Selank Rat Study Found About GABA Related Gene Expression

    Selank is a synthetic peptide based on tuftsin. It has been studied in relation to GABA, a neurotransmitter that participates in regulating nervous system activity. An older laboratory study tested whether gene expression in rat brain tissue changed after exposure to Selank.

    Selank1 source (2016)

  • Explore study findings

    Why two approval records describe different ingredients

    Semaglutide is a modified peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This entry names both molecules together.

    SEMA / IGF-1 LR33 sources (2023–2026)

  • Explore study findings

    What IGF-1 LR3 did in a lab-made skin model

    Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered version of a growth-factor protein. A 2026 tissue-engineering study used IGF-1 LR3 to investigate how cells build a supporting matrix in reconstructed skin tissue.

    SEMA / IGF-1 LR32 sources (2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)